PROGRAM MENU
Educational Program

THSNA programming is focused on presenting the most current issues in Hemostasis and Thrombosis. The THSNA 2020 program will include on demand access to recorded talks covering four educational tracks as well as live panel discussion sessions, a nursing workshop, digital posters, corporate symposia, and a virtual exhibit hall with commercial booths.

Note that all timea are listed in Eastern Daylight Time (EDT) and any aspect of this program is subject to change.

  Tue - Oct 27      Wed - Oct 28      Thu - Oct 29      Fri - Oct 30   

THURSDAY, OCTOBER 29

10:00 - 11:30 AM
PLENARY SESSION
PLENARY 3: ENSURING AND PROMOTING BEST CARE
Chair/Organizer: Robert Sidonio, Cathy Hayward

This Plenary will provide unique, expert perspectives on the challenges of ensuring that the best care is provided to persons with thrombosis or bleeding problems. The speakers will touch on broad issues that influence the quality of care, from choices between treatments to advocacy and health promotion.



PROMOTING PATIENT SAFETY
Jesse Roach.


CHOOSING BETWEEN NEW AND OLD THERAPIES FOR THROMBOSIS
Stephan Moll. Unviersity of North Carolina School of Medicine


ENSURING THE BEST CARE FOR PATIENTS WITH CONGENITAL AND ACQUIRED BLEEDING PROBLEMS. WHAT ARE OUR CHALLENGES
Len Valentino.

12:15 - 1:15 PM
SATELLITE SYMPOSIUM
CORPORATE LUNCH SYMPOSIUM: PFIZER MEDICAL SYMPOSIUM: PERSPECTIVES ON HEMOPHILIA B CARE IN AN ERA OF ADVANCED THERAPEUTICS AND EXTRAVASCULAR FIX SCIENCE: PAST, PRESENT AND FUTURE CONSIDERATIONS

Sponsored By: Pfizer

The field of hemophilia has rapidly evolved over the last decade, with a plethora of treatment options currently available, and in clinical development. Historically, the management of hemophilia B has been largely extrapolated from our scientific and clinical understanding of hemophilia A. However, a renewed focus on research in hemophilia B is changing our understanding of the science underpinning this disease and further expanding possibilities for these patients.

In this era of rapidly evolving science and technology, it is important to reflect on current management strategies for people with hemophilia B, to support the preservation of joint function and optimize the potential offered by future approaches to care.

Our satellite symposium will explore mechanisms for advancing the care of people with hemophilia B in this era of advanced therapeutics. Through discussing the role of real-world data, and our expanding understanding of the science of hemophilia B, we will explore how this progress is driving innovation and resetting our expectations of standards of care.



CORPORATE LUNCH SYMPOSIUM: PROVEN BLEED PROTECTION WITH EXTENDED FACTOR IX DOSING: LEARN MORE ABOUT THE EXTENSION STUDIES

Sponsored By: CSL Behring

Join us as we discuss NEW published data from two extension studies, affirming long-lasting efficacy with up to 4 years of evaluating adult and adolescent patients treated prophylactically at both 7- and 14-day extended intervals.


2:00 - 3:30 PM
BASIC SCIENCE
NEW INSIGHTS ON MECHANISMS
Chair/Organizer: Shannon Meeks , Rodney Camire


ADVANCES IN UNDERSTANDING THE COFACTOR FUNCTIONS OF FACTOR V AND FACTOR VIII
Rodney Camire. University of Pennsylvania/Children's Hospital of Philadelphia


UPDATE ON THE INTERPLAY BETWEEN COAGULATION AND COMPLEMENT SYSTEMS
Edward Conway. University of British Columbia Centre for Blood Research


UNDERSTANDING THE CLOT FROM STUDIES OF FIBRIN AND FACTOR XIII
JW Weisel. University of Pennsylvania

2:00 - 3:30 PM
HEMOSTASIS
NEW STRATEGIES IN HEMOPHILIA THERAPY
Chair/Organizer: Michael Recht, Mihir Bhatt


CHALLENGING BLEEDING EVENTS IN PATIENTS ON NOVEL HEMOPHILIA THERAPIES
Glaivy Batsuli.


HOW NEW THERAPIES ARE IMPACTING HEMOPHILIA TREATMENT CENTERS
Chris Guelcher. Michigan Medicine


TOLERANCE IN THE AGE OF NON-FACTOR REPLACEMENT THERAPY
Shannon Meeks. Emory University/Children's Healthcare of Atlanta

2:00 - 3:30 PM
THROMBOSIS / LABORATORY
STARTING AND STOPPING DOACS
Chair/Organizer: Arthur Allen, Pall Onunderson


PLANNED INTERRUPTION OF DOAC THERAPY
James Douketis. McMaster University


EMERGENCY REVERSAL OF DOAC THERAPY: CURRENT EVIDENCE ON BEST APPROACHES
Deb Siegal. McMaster University


LABORATORY SUPPORT FOR PATIENTS ON DOAC THERAPY: CHALLENGES TO CHECKING FOR DRUG AND MEASURING LEVELS
Adam Cuker. University of Pennsylvania

4:15 - 5:45 PM
HEMOSTASIS / LABORATORY
EVALUATING FOR BLEEDING DISORDERS: WHAT TO DO AFTER THE PATIENT WALKS THROUGH YOUR DOOR
Chair/Organizer: Stacy Croteau, Maria Santaella


BLEEDING ASSESSMENT: KEY ISSUES FOR PATIENT EVALUATION FOR CLINICAL PRACTICE AND RESEARCH ACROSS THE AGE SPECTRUM.
Sarah O'Brien.


OVERVIEW ON THE LABORATORY ASSESSMENT OF PATIENTS REFERRED FOR BLEEDING PROBLEMS.
Cathy Hayward. McMaster University, Hamilton Regional Laboratory Medicine Program


NURSING PERSPECTIVES ON THE NEEDS OF PATIENTS WITH BLEEDING PROBLEMS, WITH CONSIDERATION OF THEIR QUALITY OF LIFE.
James Munn.

4:15 - 5:45 PM
BASIC SCIENCE
NEW INSIGHTS ON PLATELETS AND THEIR FUNCTIONS
Chair/Organizer: A. Koneti Rao, Jorge DiPaola


PLATELET THIOL ISOMERASES: BENCH TO BEDSIDE
Robert Flaumerhaft.


PLATELET-LEUKOCYTE INTERACTIONS MEDIATE STROKE OUTCOMES
Matthew Rondina.


DETERMINANTS OF PLATELET HYPERREACTIVITY WITH AGING
Jorge DiPaola.

4:15 - 5:45 PM
THROMBOSIS
RISK AND BENEFITS OF COMBINATION ANTITHROMBOTIC THERAPY IN CAD: WHEN LESS IS MORE
Chair/Organizer: Eric Grabowski, Deborah Siegal


IS THERE ANY ROLE FOR ASPIRIN IN THE TREATMENT OR PREVENTION OF VENOUS THROMBOSIS?
David Garcia. University of Washington


STABLE CAD AND PERIPHERAL ARTERIAL DISEASE: WHEN SHOULD AN ANTICOAGULANT BE CONSIDERED FOR ADDED PROTECTION
Renato Lopes.


UPDATE ON RESPONSIVENESS TO ANTIPLATELET THERAPY
Santiago Nava.

6:00 - 7:00 PM
SATELLITE SYMPOSIUM
ON-DEMAND SYMPOSIUM: A BREAKTHROUGH IN ATTP TREATMENT: NOW RECOMMENDED BY THE ISTH GUIDELINES

Sponsored By: Sanofi Genzyme

The program will provide an overview of acquired thrombotic thrombocytopenic purpura (aTTP) a rare, life-threatening, auto-immune disease - and the urgency for rapid diagnosis and treatment. The program will then review the recently published ISTH Guidelines on the diagnosis and treatment of aTTP with a focus on the first and only FDA-approved therapy indicated for adults with aTTP.

View full prescribing information for an aTTP product here.

MAT-US-2019445-v1. 0-09/2020



ON-DEMAND SYMPOSIUM: HEMOPHILIA A WITHOUT INHIBITORS: PERSONALIZING THERAPY WITH FACTOR VIII PROPHYLAXIS

Sponsored By: Takeda Pharmaceuticals U. S. A, Inc.

Clinicians and patients face challenges in current factor VIII replacement therapy, including the frequency of intravenous factor infusions as well as patient adherence. Lack of adherence to prophylactic treatment leads to increased frequency of bleeds and development of hemophilic arthropathy. New treatment options for patients with hemophilia A offer the potential for more effective and convenient treatments, including new and emerging prolonged half-life clotting factors such as FVIII-Fc and pegylated FVIII, that offer a therapeutic option with decreased bleeding rates and less frequent infusions. In this case-based, one-hour pre-recorded virtual symposium, renowned hemophilia experts Michael Callaghan, MD, Miguel Escobar, MD, and Guy Young, MD, provide their perspectives on recent changes in Factor VIII replacement therapy management that are improving patient care.

Continuing Education Information: In accordance with ACCME, ANCC, and ACPE requirements, activities are certified for credit through CCO. This program will be certified by CCO for AMA PRA Category 1 Credit, ACPE contact hours, and ANCC contact hours.
Please click on the following link to obtain CME. https://www. clinicaloptions. com/event/HemophiliaChicago2020Eval

Questions? Email customersupport@clinicaloptions. com



ON-DEMAND SYMPOSIUM: MORE THAN ABRS (ANNUAL BLEED RATES): HCP AND PATIENT PERSPECTIVES IN AN EVOLVING HEMOPHILIA TREATMENT LANDSCAPE

Sponsored By: Sanofi Genzyme, Intended for US Healthcare Professionals Only

The use of factor replacement therapy in the treatment of hemophilia has come a long way and continues to change. Join us for a discussion looking beyond ABRs and at how this evolution impacts how we think about treatment approaches for different patients. Topics will include HCP and patient perspectives on how clinical data translate into real world, innovative approaches to patient engagement, with an emphasis on bleed and joint bleed protection. Please see important safety information throughout this presentation and full prescribing information at the links provided below.

Full Prescribing Information for a Hemophilia A treatment
Full Prescribing Information for a Hemophilia B treatment

MAT-US-2021089 v1. 0 10/2020


7:00 - 8:00 PM
SHORT TALKS
BLEEDING DISORDER IMPACT


LONG-TERM IMMUNOGENICITY, EFFICACY AND TOLERABILITY OF SIMOCTOCOG ALFA IN PATIENTS WITH SEVERE HAEMOPHILIA A WHO HAD COMPLETED THE NUPROTECT STUDY
Ellis J Neufeld1, Ri J Liesner2, on behalf of the GENA-15 Study Group1. 1St. Jude Children, Memphis, TN, USA. 2Haemophilia Comprehensive Care Centre, Great Ormond Street Hospital for Children, NHS Foundation Trust, London, United Kingdom


CHARACTERISTICS, COMPLICATIONS, AND SITES OF BLEEDING AMONG INFANTS AND TODDLERS LESS THAN 2 YEARS OF AGE WITH VWD: A REPORT FROM THE UNIVERSAL DATA COLLECTION SURVEILLANCE PROJECT.
Brandi Dupervil 1, Karon Abe1, Sarah O'Brien2, Meredith Oakley1, Roshni Kulkarni3, Vanessa Byams1, Mike Soucie1. 1Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, USA. 2The Research Institute a Nationwide Children, Columbus, OH, USA. 3Centers for Bleeding and Clotting Disorders, Department of Pediatrics and Human Development, Michigan State University, East Lansing, MI, USA


HEAVY MENSTRUAL BLEEDING IMPACT ON MENTAL HEALTH IN ADOLESCENT AND YOUNG ADULT WOMEN WITH BLEEDING DISORDERS
Mary McGrath1, Elisabeth Quint2, Angela Weyand1. 1Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA. 2Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, USA


SOCIALLY VULNERABLE YOUTH WITH BLEEDING DISORDERS: PILOTING NOVEL INTERVENTIONS IN CHILDREN'S HEALTHCARE (NICH)
David V Wagner, Michael Recht, Susan Lattimore, Kristina Haley, Erin Stang, Kim Spiro, Michael A Harris. Oregon Health and Science University, Portland, OR, USA


BLEEDING DISORDER THERAPY AND OUTCOMES


INCREASED HEMOPHILIA-RELATED DISTRESS IS ASSOCIATED WITH REDUCED ADHERENCE TO FACTOR REPLACEMENT THERAPY.
Sara A. Guasch1, Janet Figueroa 1, Vaughn Barry1, Shanna Mattis1, Tyler W. Buckner2, Duc Q. Tran1, Stephanie Whitten 1, Christine L. Kempton 1. 1Emory University, Atlanta, GA, USA. 2University of Colorado, Aurora, CO, USA


PATIENTS WITH G-HSD/HEDS EVALUATED AT HTCS HAVE SIMILAR CO-MORBIDITES TO THOSE IN THE GENERAL POPULATION
Rohith Jesudas1, Christopher Eberlin2, Sweta Gupta3, Amit Soni4, Diane Neugent4, Nina Hwang4, Vanessa Salinas4, Nicole Crook4, Ateefa Chaudhury4, Christina Laukaitis5. 1Bleeding and clotting disorders institute, Peoria, IL, USA. 2University of Illinois College of Medicine in Peoria, Peoria, IL, USA. 3Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA. 4Center for Inherited Blood Disorders, Orange, CA, USA. 5University of Arizona, Tucson, AZ, USA


HEMATOLOGY PROVIDER ATTITUDES AND PRACTICES REGARDING IUD INSERTION IN ADOLESCENTS WITH HEAVY MENSTRUAL BLEEDING WITH AND WITHOUT BLEEDING DISORDERS
Allison Wheeler1, Katherine O'Flynn O'Brien2, Claudia Borzutzky3, Peter Kouides4, Oluyemisi Adeyemi-Fowode2. 1Vanderbilt University Medical Center, Nashville, TN, USA. 2Texas Children's Hospital, Houston, TX, USA. 3Children's Hospital of Los Angeles, Los Angeles, CA, USA. 4Mary M Gooley Hemophilia Treatment Center, Rochester, NY, USA


INHERITED AND ACQUIRED BLEEDING DISORDERS


SECOND-LINE THERAPY WITH FOSTAMATINIB IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP)
Ralph Boccia1, Waleed Ghanima2, Quentin Hill3, Michelle Sholzberg4, Michael D Tarantino5, Darla Liles6, Yuliya Kreychman7, Robert P Numerof7, Sonia Souza7, Leslie Todd7, Sandra Tong7, James B Bussel8. 1Center for Cancer and Blood Disorders, Bethesda, MD, USA. 2Department of Research, Ostfold Hospital Trust, Sarpsborg and Department of Hematology, Institute of Clinical Medicine, Sarpsborg, Norway. 3Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom. 4Li Ka Shing Knowledge Institute, St. Michael, Toronto, ON, Canada. 5The Bleeding and Clotting Disorders Institute, University of Illinois College of Medicine-Peoria, Peoria, IL, USA. 6East Carolina University Brody School of Medicine, Greenville, NC, USA. 7Rigel Pharmaceuticals, Inc, South San Francisco, CA, USA. 8New York Presbyterian Hosp. Weill Cornell Medical Center, New York, NY, USA


SCREENING FOR FACTOR IX PADUA (R338L) IN PEDIATRIC THROMBOSIS PATIENTS
Benjamin J Samelson-Jones1, 2, 3, James F. Jarrett III1, Leslie J. Raffini1, 2, Valder R. Arruda1, 2, 3. 1The Children's Hospital of Philadelphia, Philadelphia, PA, USA. 2Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 3Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Philadelphia, PA, USA


ASSESSMENT OF RARE BLEEDING DISORDERS IN ADOLESCENT FEMALES WITH UNEXPLAINED BLEEDING
Ruchika Sharma1, 2, Seema Menon2, Michelle Dobratz1, Bridgit Hansen1, Victoria Johnson1, Veronica Flood1, 2. 1Versiti Blood Center of Wisconsin, Milwaukee, WI, USA. 2Medical College of Wisconsin, Milwaukee, WI, USA

7:00 - 7:45 PM
POSTER SESSION
POSTER SESSION 5


A2. PLATELET ACTIVATION AND BIOCHEMISTRY


0

EVIDENCE OF THE P75 PAN-NEUROTROPHIC RECEPTOR IN PLATELETS AND COMPARISON TO THE ISOFORM FOUND IN THE BRAIN
Samuel Fleury1, 2, Imane Boukhatem1, 2, Jessica Le Blanc1, 2, Melanie Welman1, Marie Lordkipanidze1, 2. 1Montreal Heart Institute, Montreal, QC, Canada. 2Faculty of Pharmacy, Universite de Montreal, Montreal, QC, Canada


163

APOLIPOPROTEIN A-IV IS AN ENDOGENOUS INHIBITOR OF THROMBOSIS: THE ROLES OF POLYMORPHISMS IN THE RISK OF CARDIOVASCULAR DISEASE
Si-Yang Yu1, 5, Daniel MacKeigan1, 2, 4, Miguel Neves1, 6, 7, Pingguo Chen1, 6, 7, Heyu Ni1-4, 6, 7. 1Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael, Toronto, ON, Canada. 2Department of Physiology, University of Toronto, Toronto, ON, Canada. 3Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. 4Faculty of Medicine, University of Toronto, Toronto, ON, Canada. 5Department of Cardiovascular Medicine, The Second Xiangya Hospital of Central South University, Changsha, China. 6Canadian Blood Services Centre for Innovation, Toronto, ON, Canada. 7Toronto Platelet Immunobiology Group, Toronto, ON, Canada


A4. DISORDERS OF PLATELET NUMBER OR FUNCTION


70

IMPACT OF FIRST LINE CORTICOSTEROID CHOICE ON PATIENT OUTCOMES IN ACUTE IMMUNE THROMBOCYTOPENIA
Sowda Ahmed, Maureen Laschen, Surbhi Shah. University of Minnesota Medical School, Minneapolis, MN, USA


71

EVALUATION OF LIGHT TRANSMISSION AGGREGOMETRY ON THE ROUTINE COAGULATION ANALYZER SYSMEX CS-2500
Safaa Mghinia1, 2, Yamna lanouari1, 2, mohamed nady1, karima mikou3, Bouchra Oukkache1, 2. 1Hematology Laboratory, CHU Ibn Rochd, Casablanca, Morocco. 2Hassan II University of Casablanca, Faculty of Medicine and Pharmacy, Casablanca, Morocco. 3Scientific Department, Megaflex sarl, Casablanca, Morocco


72

GAUCHER DISEASE SCREENING IN PATIENTS WITH THROMBOCYTOPENIA: A CROSS-SECTIONAL STUDY
Vidushi Swarup1, Nicole Veloce1, Aziz Jiwajee1, Hina R Hanif1, 4, Pauline Manuel1, Gloria Lim1-3, Rosane Nisenbaum5, Cyrus Hsia6, Michelle Sholzberg1-5. 1Hematology-Oncology Clinical Research Group, St. Michael's Hospital, Toronto, ON, Canada. 2Division of Hematology, Department of Medicine, St. Michael's Hospital, Toronto, ON, Canada. 3Department of Medicine, University of Toronto, Toronto, ON, Canada. 4Department of Laboratory Medicine and Pathobiology, St. Michael's Hospital, Toronto, ON, Canada. 5Applied Health Research Centre, MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada. 6Division of Hematology, Department of Medicine, London Health Sciences Centre, Toronto, ON, Canada


A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS


0

ORDER SET MODIFICATION PROMOTES EFFECTIVE LABORATORY TEST UTILIZATION IN THE DIAGNOSIS OF HIT
Michael Kimbrell1, 2, Matthew Butters2, Mikhail Akbashev2. 1University of Texas Southwestern, Dallas, TX, USA. 2Emory University School of Medicine, Atlanta, GA, USA


73

FIBRINOGEN COLUMBUS III: A NOVEL C. 963DEL FRAMESHIFT MUTATION IN FGG RESULTING IN HYPOFIBRINOGENEMIA AND BLEEDING
Eman Abdelghani1, Jennifer Dawson2, Kristin Zajo1, Michelle Hallam1, Riten Kumar 1. 1Division of Pediatric Hematology/Oncology/BMT, Nationwide Children, Columbus, OH, USA. 2Department of Structural Biology, St. Jude Children, Memphis, TN, USA


74

DIFFERENTIAL FIBRINOLYSIS DYNAMICS IN PERIPARTUM WOMEN BASED ON THE ROUTE OF DELIVERY
Maria Cristina Bravo, Thomas Orfeo, Kelley McLean, Ira Bernstein, Kathleen Brummel-Ziedins. University of Vermont, Burlington, VT, USA


75

COMBINED INHERITED AND ACQUIRED VON WILLEBRAND DISEASE: AN UNRECOGNIZED ENTITY
Maria DeSancho1, Kenneth Friedman2. 1Weill Cornell Medicine, New York, NY, USA. 2Blood Center of Wisconsin, Milwaukee, WI, USA


76

ANTI-TFPI ANTIBODY BAY 1093884: EARLY TERMINATION OF PHASE II STUDY DUE TO THROMBOSIS
Francesca Ferrante1, Sheila Ingham2, Marc Kunze3, Lisa A Michaels4. 1Bayer, Basel, Switzerland. 2Bayer, Sao Paulo, Brazil. 3Bayer, Berlin, Germany. 4Bayer, Whippany, NJ, USA


77

EFFICACY AND SAFETY OF “HALF-DOSE” DESMOPRESSIN FOR BLEEDING PROPHYLAXIS IN BLEEDING DISORDER PATIENTS UNDERGOING INVASIVE PROCEDURES
Fateeha Furqan1, Ronald Sham2, Peter Koiudes2. 1Department of Internal Medicine, Rochester General Hospital, Rochester, NY, USA. 2Department of Hematology and Oncology, Rochester General Hospital, Rochester, New York and the Mary M. Gooley Hemophilia Treatment Center of Rochester, Rochester, NY, USA


78

DIFFERENTIAL DIAGNOSIS FOR SWELLING OF THE SCALP IN INFANCY
Michelle M Hallam1, Amy L Dunn1, 2. 1Nationwide Children's Hospital, Columbus, OH, USA. 2Ohio State University Wexner Medical Center, Columbus, OH, USA


79

THE INTEGRATED ROLE OF C-REACTIVE PROTEIN, NITRIC OXIDE, DDIMER, MYELOPEROXIDASE, AND PLASMINOGEN ACTIVATOR INHIBITOR-1 IN THE PATHOGENESIS OF END STAGE RENAL DISEASE
Meriam Ben Hadj Tahar, Vinod Bansal, Emily Bontekoe, Alyssa Abrenica, Debra Hoppensteadt, Alek Druck, Jawed Fareed. Loyola University Medical Center, Maywood, IL, USA


80

A RARE ETIOLOGY FOR WARFARIN SENSITIVITY IN A 28 YEAR OLD MALE
Natasha Pardy. Memorial University of Newfoundland, St. John's, NL, Canada


82

FAILURE OF MULTIPLE CONCURRENT ANTITHROMBOTIC AGENTS IN THE TREATMENT OF RECURRENT VENOUS THROMBOEMBOLISM IN A PATIENT WITH ELEVATED FACTOR VIII LEVELS
Bassil Said1, Mehul Patel2, Peter Kouides2. 1Rochester General Hospital, Department of Internal Medicine, Rochester, NY, USA. 2Rochester General Hospital, Lipson Cancer Center, Rochester, NY, USA


83

LABORATORY ASSESSMENT AND OPTIMIZATION OF A FVIII INHIBITOR ELISA KIT
Meera Sridharan, Katrina McGaffey, Julie Tange, Dong Chen , Rajiv Pruthi . Mayo Clinic, Rochester, MN, USA


84

PERIOPERATIVE MANAGEMENT OF PATIENTS WITH HEMOPHILIA RECEIVING FITUSIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC TARGETING ANTITHROMBIN FOR THE TREATMENT OF HEMOPHILIA
K. John Pasi1, Claude Negrier2, Margaret V. Ragni3, Pencho Georgiev4, Vasily Mamonov5, Toshko Lissitchkov 6, Kichou Salim7, Baisong Mei7, Shauna Andersson7. 1Royal London Hospital Haemophilia Centre, Barts and The London School of Medicine and Dentistry, London, United Kingdom. 2Unite d, Lyon, France. 3Department of Medicine and Hemophilia Center of Western Pennsylvania, University of Pittsburgh, Pittsburgh, PA, USA. 4University Multiprofile Hospital for Active Treatment Sveti Georgi and Medical University Plovdiv, Plovdiv, Bulgaria. 5National Research Center for Hematology, Moscow, Russia. 6 Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Bulgaria. 7Sanofi, Cambridge, MA, USA


A7. PATHOPHYSIOLOGY OF THROMBOSIS


85

PHYSICAL ACTIVITY IN CHILDREN AT RISK OF POST-THROMBOTIC SYNDROME (PACT): A PILOT RANDOMIZED CONTROLLED TRIAL
Rida Hasan 1 , Maria Hanna1, Kendra Malone2, Song Zhang1, Ravi Sarode 1, Janna Journeycake3, Ayesha Zia1. 1University of Texas Southwestern Medical Center, Dallas, TX, USA. 2Children's Medical Center, Dallas, TX, USA. 3University of Oklahoma Health Science Center, Oklahoma City, OK, USA


86

UPREGULATION OF C-REACTIVE PROTEIN, PLASMINOGEN ACTIVATOR INHIBITOR-1, MMP-9, FIBRONECTIN, AND OSTEOPONTIN FOLLOWING TOTAL KNEE REPLACEMENT AND HIP REPLACEMENT SURGERY (TKA AND THA).
Maryanne Amour, Fakiha Siddiqui, Debra Hoppensteadt, Meriam Ben Hadj Tahar, Jawed Fareed. Loyola University Medical Center, Maywood, IL, USA


87

VENOUS THROMBOEMBOLISM HOSPITALIZATION AND RELATED DEATH: ANALYSIS OF THE NATIONWIDE READMISSIONS DATABASE
Guillermo Tafur1, Alfonso Tafur2, Kambiez Zorriasateyn2, Cheong Lee2. 1Loyola University Medical Center, Maywood, IL, USA. 2Northshore University health Systems, Skokie, IL, USA


88

TITLE: UPSHAW SCHULMAN SYNDROME IS A RARE MASQUERADER OF ATYPICAL HEMOLYTIC SYNDROME & THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) IN PREGNANCY RELATED THROMBOTIC MICROANGIOPATHY (P-TMA).
Fnu Kaweeta, Sandeep K Rajan. UTHSC, Memphis, TN, USA


A8. ANTITHROMBOTIC THERAPY


0

EFFECTIVENESS AND SAFETY OF PRIMARY THROMBOPROPHYLAXIS IN PEDIATRIC RENAL TRANSPLANT: A SYSTEMATIC REVIEW OF THE LITERATURE AND META-ANALYSIS
Ahmad Al-Huniti, Caroline Malcolmson, Armando Lorenzo, Valerie Langlois, Suzan Williams, Chia Wei Teoh, Leonardo Brandao. The hospital for sick children, Toronto, ON, Canada


A9. INFORMATIONAL ABSTRACT (POSTER ONLY)


89

ENGAGING PATIENTS AND FAMILIES AT EMICIZUMAB INITIATION
Madolyn Hofstetter, Kelsey Smith, Susan U Lattimore. Oregon Health a Science University, Portland, OR, USA


90

SUCCESSFUL USE OF TISSUE PLASMINOGEN ACTIVATOR IN INFANTS WITH LIFE THREATENING THROMBOSIS ON EXTRACORPOREAL MEMBRANE OXYGENATION LIFE SUPPORT - A CASE REPORT
Dena R Wideman1 , Kristina A D'Agostino1. 2. 1Children's Mercy, Kansas City, MO, USA. 2University of Missouri Kansas City, Kansas City, MO, USA


91

DISEASE BURDEN AND HEALTHCARE UTILIZATION AMONG PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA EXPERIENCING CHRONIC PAIN: ANALYSES FROM A NATIONAL HEALTHCARE DATABASE
Samuel M. Silver 1, Angelika L. Erwin 2, Stephen Meninger3, Joseph Tkacz4, Virgina Noxon4, John J. Ko3. 1University of Michigan Medical Center, Ann Arbor, MI, USA. 2Cleveland Clinic, Cleveland, OH, USA. 3Alnylam Pharmaceuticals, Cambridge, MA, USA. 4IBM Watson Health, Bethesda, MD, USA


164

U. S. EMERGENCY DEPARTMENT VISITS FOR ORAL ANTICOAGULANT-RELATED BLEEDING, 2018
Andrew I. Geller1, Maribeth C. Lovegrove1, Daniel S. Budnitz1, Nadine Shehab2. 1Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA. 2Lantana Consulting Group, contractor to the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA


POSTER SESSION 6


A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS


0

EMICIZUMAB IN ACQUIRED HEMOPHILIA A
Sheh-Li Chen1, Raj S Kasthuri2, Alice D Ma2, Stephan Moll2, Nigel S Key2. 1Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA. 2Department of Medicine, Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA


0

AWARENESS AND MANAGEMENT OF BLEEDING DISORDER AMONGST DENTAL PRACTITIONERS IN ENUGU, SOUTH EAST, NIGERIA.
Helen C. Okoye1, Chilota C. Efobi2, Kaladada I. Korubo3, Anazoeze J. Madu1, Felix N. Chukwuneke4. 1Department of Haematology, College of Medicine, University of Nigeria Ituku Ozalla campus, Enugu, Nigeria. 2Department of Haematology and Blood Transfusion, College of Health Sciences, Nnamdi Azikiwe University Nnewi campus, Anambra, Nigeria. 3Department of Haematology and Blood Transfusion, University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria. 4Department of Oral and Maxillofacial surgery, Faculty of Dentistry, College of Medicine, University of Nigeria, Ituku Ozalla campus Enugu Nigeria, Enugu, Nigeria


A7. PATHOPHYSIOLOGY OF THROMBOSIS


0

THE RATIO OF VON WILLEBRAND FACTOR:ANTIGEN / ADAMTS-13 IN CANCER PATIENTS WITH CHEMOTHERAPY AS DISCRIMINANT VARIABLE TO PREDICT EARLY DEEP VEIN THROMBOSIS
Ridho M. Naibaho1, 2, Budi Setiawan3, Eko A. Pangarsa3, Damai Santosa3, Suyono Suyono3, Mika Lumbantobing3, Catharina Suharti3. 1Fellow in Hematology and Medical Oncology, Semarang, Indonesia. 2Dept. of Medicine, Medical Faculty of Mulawarman University and Parikesit Hospital, Kutai Kartanegara, Indonesia. 3Division of Hematology and Medical Oncology, Dept. of Medicine, Medical Facultty of Diponegoro University and Dr. Kariadi Hospital, Semarang, Indonesia


A8. ANTITHROMBOTIC THERAPY


93

IS THERE A NEED FOR ANTICOAGULATION FOR NEW-ONSET ATRIAL FIBRILLATION IN SEPSIS: A NARRATIVE REVIEW
Jesus Aibar1, 2, Sam Schulman2. 1Internal Medicine Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain. 2Department of Medicine, Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada


94

STANDARDIZATION OF DIRECT ORAL ANTICOAGULANT MANAGEMENT ACROSS A HEALTH SYSTEM
J Burdick, C Patterson, A Rose. University of Wisconsin Hospital and Clinics, Madison, WI, USA


95

GENOME-WIDE ANALYSIS OF WARFARIN PHARMACOGENOMICS IN PATIENTS FROM THE MIDDLE EAST AND NORTH AFRICAN REGION
Nihal El Rouby1, Mohamed Shahin2, Loulia Bader3, Hazem Elewa3. 1University of Cincinnati, Cincinnati, OH, USA. 2Pfizer Global Research, Groton, CT, USA. 3College of Pharmacy, Qatar University, Doha, Qatar


96

SULODEXIDE AS A PARENTERAL ANTICOAGULANT. A SUBSTITUTE FOR UNFRACTIONATED HEPARIN.
Bharathi Daravath1, Emily Bontekoe1, Ahmed Kouta1, Omer Iqbal1, Christopher Lattimer2, Jawed Fareed1. 1Loyola University Medical Center, Maywood, IL, USA. 2Ealing Hospital, London United Kingdom


97

USP POTENCY EQUATED BOVINE MUCOSAL HEPARINS ARE COMPARABLE TO PORCINE MUCOSAL HEPARIN AND MAY BE INTERCHANGEABLE FOR ANTICOAGULATION.
Ahmed Kouta, Walter Jeske, Debra Hoppensteadt, Massimo Iacobelli, Omer Iqbal, Jawed Fareed. Loyola University Medical Center, Maywood, IL, USA


98

SHEEP MUCOSAL HEPARIN AS A SUBSTITUTE FOR PORCINE MUCOSAL HEPARIN. A VIABLE OPTION TO ADDRESS THE POTENTIAL SHORTAGE CRISIS.
Ahmed Kouta1, Jawed Fareed1, Walter Jeske1, Debra Hoppensteadt1, Omer Iqbal1, Emily Bontekoe1, Massimo Iacobelli1, Yiming Yao2. 1Loyola University Medical Center, Maywood, IL, USA. 2Ronnsi Pharma, LTD, Suzhou China


99

WHOLE BLOOD ANTICOAGULANT EFFECTS OF SULODEXIDE AS MEASURED BY ACTIVATED CLOTTING TIME AND THEIR NEUTRALIZATION BY PROTAMINE SULFATE
Bharathi Daravath, Omer Iqbal, Debra Hoppensteadt, Jawed Fareed. Loyola University Medical Center, Maywood, IL, USA


100

DIFFERENCES IN THE CLOT BASED AND AMIDOLYTIC ANTI-XA ASSAYS BETWEEN THE NEUTRALIZATION PROFILE OF APIXABAN, BETRIXABAN, EDOXABAN AND RIVAROXABAN
Fakiha Siddiqui1, Alfonso Tafur2, Debra Hoppensteadt1, Emily Bontekoe1, Walter Jeske1, Bruce Lewis1, Omer Iqbal1, Jawed Fareed1. 1Loyola University Medical Center, Maywood, IL, USA. 2Northshore Health Systems, Skokie, IL, USA


101

ENHANCEMENT OF THROMBIN GENERATION IN LYMPHOMA COHORT BY ANDEXANET ALFA
Fakiha Siddiqui1, Emily Bontekoe1, Darko Antic2, Debra Hoppensteadt1, Grigoris Gerotziafas3, Ismail Elalamy3, Jawed Fareed1. 1Loyola University Medical Center, Maywood, IL, USA. 2Clinical Center for Hematology, Belgrade Serbia. 3Tenon University Hospital, Paris France


102

EVALUATION OF ANTICOAGULATION PHARMACOTHERAPY AND CLINICAL OUTCOMES FOR ACUTE COMMUNITY-ACQUIRED VENOUS THROMBOEMBOLISM DIAGNOSED IN THE EMERGENCY DEPARTMENT
Thao N. Huynh1, Matthew E. Borrego1, Allison E. Burnett1, 2, Lisa R. Koselke2, Dusadee Sarangarm2, 3, Gregory C. Hadlock4. 1University of New Mexico College of Pharmacy, Albuquerque, NM, USA. 2University of New Mexico Hospital, Albuquerque, NM, USA. 3University of New Mexico Department of Emergency Medicine, Albuquerque, NM, USA. 4Presbyterian Healthcare Services, Albuquerque, NM, USA


103

CHARACTERISTICS, MANAGEMENT, AND OUTCOMES OF PATIENTS RECEIVING ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE FOR APIXABAN AND RIVAROXABAN ASSOCIATED MAJOR BLEEDING
John M. Koerber1, 3, Karissa Fritsch1, Janet L. Hoffman1, 3, Sean Mertz2, Nour Baalbaki1, Fatme Chehab3, Maureen A. Smythe1, 3. 1Beaumont Heatlh, Royal Oak, MI, USA. 2Cleveland Clinic, Cleveland, OH, USA. 3Wayne State University, Detroit, MI, USA


104

MANAGEMENT OF PULMONARY EMBOLISM AND CEREBRAL VENOUS SINUS THROMBOSIS IN CHILDREN WITH LEUKEMIA
Melanie Degliuomini1, 2, Victoria Cooley3, Elizabeth Mauer3, Linda Gerber3, Suchitra Acharya4, Nicole Kucine1. 1Weill Cornell Medicine, Department of Pediatrics, New York, NY, USA. 2Memorial Sloan Kettering Cancer Center, Department of Pediatrics, New York, NY, USA. 3Weill Cornell Medicine, Department of Healthcare Policy and Research, New York, NY, USA. 4Cohen Children's Medical Center, Northwell Health, New Hyde Park, NY, USA


105

THROMBOSIS AND ORAL ANTICOAGULATION IN PEDIATRICS PATIENTS: NOW IT IS POSSIBLE TO IMPROVE THE QUALITY OF LIFE AND CLINICAL SAFETY WITH THE “COAGULIN PROJECT”
RAFAEL MARTOS1, MARIA YUSTE1, ELENA GONZALEZ1, LAURA BERMEJO2, PILAR BELTRAN2, ADRIANA PASCUAL2, DELIA CORNEJO1, PILAR LLAMAS1, 2, 3. 1HOSPITAL GENERAL UNIVERSITARIO DE VILLALBA, MADRID, Spain. 2HOSPITAL UNIVERSITARIO INFANTA ELENA DE VALDEMORO, MADRID, Spain. 3HOSPITAL UNIVERSITARIO FUNDACION JIMENEZ DIAZ, MADRID, Spain


106

RETROSPECTIVE QUALITY ASSURANCE STUDY FOR POTENTIAL P2Y12 RECEPTOR INHIBITOR INTERFERENCE OF SEROTONIN RELEASE ASSAY (SRA) DETECTING ANTIBODIES ASSOCIATED WITH HEPARIN INDUCED THROMBOCYTOPENIA (HIT) IN PATIENT SPECIMENS
Morgan H. McCoy1, Charles S. Davis2, Komal A. Pandya1, George A. Davis1. 1University of Kentucky Medical Center, Lexington, KY, USA. 2University of Kentucky College of Pharmacy, Lexington, KY, USA


107

RETROSPECTIVE ANALYSIS OF FOUR FACTOR PROTHROMBIN COMPLEX CONCENTRATE USE IN EMERGENCY DEPARTMENT PATIENTS OVER THREE YEARS: A SINGLE CENTER EXPERIENCE
Hannah L McRae1, Ferhat Kara1, Nicole Acquisto2, Majed Refaai1. 1Department of Pathology and Laboratory Medicine, Transfusion Medicine Unit, University of Rochester Medical Center, Rochester, NY, USA. 2Departments of Pharmacy and Emergency Medicine, University of Rochester Medical Center, Rochester, NY, USA


108

VARIABILITY IN LOW MOLECULAR WEIGHT HEPARIN ANTI-XA ASSAYS BETWEEN MANUFACTURERS
Karen A Moffat1, 2, Siraj Mithoowani1, Akash Gupta1, Stephen A Carlino2, Mark A Crowther1. 1Department of Medicine, McMaster University, Hamilton, ON, Canada. 2Hamilton Regional Laboratory Medicine Program, Hamilton, ON, Canada


109

SUCCESSFUL TREATMENT OF PEDIATRIC CEREBRAL VENOUSTHROMBOSIS STROKEWITH BIVALIRUDIN
Oluwaseun Olaiya, Sana Farooki, Mukta Sharma. Children's Mercy Hospital, Kansas City, MO, USA


110

THERAPEUTIC DILEMMA: MANAGING PHLEGMASIA CERULEA DOLENS IN A PEDIATRIC PATIENT WITH SEVERE CHRONIC REFRACTORY IMMUNE THROMBOCYTOPENIA
Penelope Sandiford1, Melissa Rose1, Patrick Warren2, Riten Kumar1. 1Division of Hematology/Oncology/BMT, Nationwide Children's Hospital, Department of Pediatrics, The Ohio State University, Columbus, OH, USA. 2Division of Interventional Radiology, Nationwide Children's Hospital, Department of Radiology, The Ohio State University, Columbus, OH, USA


111

INTERIM RESULTS FROM A FEASIBILITY STUDY OF THE FEARON ALGORITHM IN WARFARIN PATIENT SELF-MANAGEMENT
Daniel Witt1, Sara Vazquez1, Aubrey Jones1, John Saunders1, Paul Wegner2, Michael Fearon3. 1University of Utah, Salt Lake City, UT, USA. 2Epitome Pharmaceuticals, San Diego, CA, USA. 3Epitome Pharmaceuticals, Halifax, NS, Canada


112

CLINICAL OUTCOMES FOLLOWING ADMINISTRATION OF 4F-PCC FOR MANAGEMENT OF BLEEDING OR NEED FOR EMERGENT PROCEDURE ON A XA INHIBITOR- GOOD ENOUGH, OR DO WE NEED OTHER AGENTS?
Maura K. Wychowski, Christina I. Ruscio, Ronald L. Sham, Peter A. Kouides. Rochester General Hospital, Rochester, NY, USA


A9. INFORMATIONAL ABSTRACT (POSTER ONLY)


113

UTILIZATION OF EMICIZUMAB AS TREATMENT IN ACQUIRED FACTOR VIII DEFICIENCY
Kevin J. Hess, Preysi Patel, Amogh M. Joshi, Adam J. Kotkiewicz. Lehigh Valley Health Network, Allentown, PA, USA


114

HEMOSTATIC EFFICACY OF ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE FOR REVERSAL OF APIXABAN AND RIVAROXABAN INTRACRANIAL HEMORRHAGE
John M. Koerber1, 3, Janet L. Hoffman1, 3, Sean Mertz2, Karissa Fritsch1, Nour Baalbaki3, Anant Krishnan1, Maureen A. Smythe1, 3. 1Beaumont Heatlh, Royal Oak, MI, USA. 2Cleveland Clinic, Cleveland, OH, USA. 3Wayne State University, Detroit, MI, USA


115

HEMIN USE IN PATIENTS WITH ACUTE HEPATIC PORPHYRIA TREATED WITH GIVOSIRAN: A POST HOC ANALYSIS OF THE PHASE 3 ENVISION STUDY
David Kuter 1, Sioban B. Keel 2, Laurent Gouya3, Herbert L. Bonkovsky4, Penelope E. Stein5, David C. Rees5, Samuel M. Silver 6, Charles Parker 7, Manish Thapar8, Zoe Hua9, Amy Simon 9, John J. Ko9, Petro Petrides10. 1Massachusetts General Hospital, Boston, MA, USA. 2University of Washington, Seattle, WA, USA. 3Centre Francais des Porphyries, Paris, France. 4Wake Forest University NC Baptist Health, Winston-Salem, NC, USA. 5King, London, United Kingdom. 6University of Michigan, Ann Arbor, MI, USA. 7University of Utah, Salt Lake City, UT, USA. 8Thomas Jefferson University, Philadelphia, PA, USA. 9Alnylam Pharmaceuticals, Cambridge, MA, USA. 10Hematology Oncology Center Munich, Munich, Germany


POSTER SESSION 7




0

TRANSIENT GENE THERAPY TO DECREASE THE STABILITY OF THROMBI FOR COAGULOPATHY AND THROMBOSIS
Amy Strilchuk1, 2, Scott Meixner2, Joseph Palumbo3, Ed Conway2, Ed Pryzdial2, Pieter Cullis2, Christian Kastrup1, 2. 1Michael Smith Laboratories, Vancouver, BC, Canada. 2University of British Columbia, Vancouver, BC, Canada. 3Cancer and Blood Diseases Institute, Cincinnati Children, Cincinnati, OH, USA


A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS


0

TRENDS IN D-DIMERS AND THROMBOSIS AMONG PATIENTS EVALUATED FOR COVID-19
Francois Rollin, Bhavin B Adhyaru, Afshan Idrees, Seema Tekwani, Mikhail Y Akbashev. Emory University School of Medicine, Atlanta, GA, USA


A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS


0

PREPARATION OF A NATIONAL RESEARCH AGENDA FOR THE INHERITED BLEEDING DISORDERS COMMUNITY
Michelle L. Witkop1, Michael Recht2, Donna DiMichele3, Leonard A. Valentino1. 1National Hemophilia Foundation, New York, NY, USA. 2American Thrombosis and Hemostasis Network, Rochester, NY, USA. 3Donna DiMichele Consulting, LLC, Washington, DC, USA


139

DIGITAL MONITORING OF PHYSICAL ACTIVITY VIA APP QUESTIONNAIRES IN PATIENTS WITH BLEEDING DISORDERS.
Marc Lara1, Suchitra Acharya2, Joseph Stanco2, Maissaa Janbain3, Amina Rafique3, Angela Kellum3, Robert Sidonio4, Guy Young5, Michael Callaghan6, Meera Chitlur6. 1MicroHealth, Inc, New York, NY, USA. 2Northwell Health, New York, NY, USA. 3Tulane University School of Medicine, New Orleans, LA, USA. 4Children's Healthcare of Atlanta, Atlanta, GA, USA. 5Children's Hospital of Los Angeles, Los Angeles, CA, USA. 6Children's Hospital of Michigan, Detroit, MI


140

DOES DISTANCE TO HEMOPHILIA TREATMENT CENTER IMPACT USE OF HEMOPHILIA TREATMENT SERVICES?
Susan U Lattimore, Alysia Cox, Kristina M Haley, Madolyn T Hofstetter, Kelsey Smith. Oregon Health a Science University, Portland, OR, USA


143

TAKE CONTROL. PERIOD. - NEEDS ASSESSMENT LEADING TO THE DEVELOPMENT OF A DIGITAL QUALITY IMPROVEMENT INTERVENTION DESIGNED TO ENHANCE ADHERENCE TO TRANEXAMIC ACID AND IRON SUPPLEMENTATION IN WOMEN WITH HEAVY MENSTRUAL BLEEDING
Ying Ling1, Filomena Meffe2, Deborah Robertson2, Jessica Petrucci3, Georgina Floros3, Paula James4, Jeffrey Mosko5, Michelle Sholzberg3, 6. 1Department of Medicine, University of Toronto, Toronto, ON, Canada. 2Department of Obstetrics and Gynecology, St. Michael, Toronto, ON, Canada. 3Division of Hematology/Oncology, Department of Medicine, St. Michaels Hospital, Toronto, ON, Canada. 4Division of Hematology, Department of Medicine, Queen, Kingston, ON, Canada. 5Division of Gastroenterology, Department of Medicine, St. Michael, Toronto, ON, Canada. 66Department of Laboratory Medicine and Pathology, St. Michael, Toronto, ON, Canada


144

ENDOGENOUS THROMBIN POTENTIAL (ETP) IS SIGNIFICANTLY MORE ENHANCED BY EMICIZUMAB IN THROMBIN GENERATION ASSAY (TGA) PERFORMED WITH PLATELET RICH PLASMA (PRP) AS OPPOSED TO PLATELET POOR PLASMA (PPP)
Erika J Martin1, Gita V Massey2, Janice G Kuhn1. 1Virginia Commonwealth University, Richmond, VA, USA. 2Children, Richmond, VA, USA


145

EMICIZUMAB AND TRAUMA: CASE REPORT OF FRACTURE, FASCIOTOMY AND SKIN GRAFTING IN A HEMOPHILIA PATIENT WITH HIGH TITER INHIBITOR
Daniel Choi, Maria Teresa DeSancho, Jeffery Laurence, Ilene Goldberg, Catherine McGuinn. Weill Cornell Medicine, New York, NY, USA


146

HEPARIN RESISTANCE IS COMMON IN PATIENTS ON EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)
Vikram Raghunathan1, 2, Patricia Liu2, Joseph Shatzel1, 2, 3. 1Division of Hematology and Oncology, Oregon Health a Science University, Portland, OR, USA. 2Department of Medicine, Oregon Health a Science University, Portland, OR, USA. 3Department of Biomedical Engineering, Oregon Health a Science University, Portland, OR, USA


148

LABORATORY CORRELATION OF THROMBIN GENERATION DATA, INCLUDING FACTOR VIII AND IX SENSITIVITIES ON AN AUTOMATED (ST GENESIA) VS. SEMI-AUTOMATED (CAT) PLATFORM
Steven Mcbryant1, Christian Nenninger1, Paul W Riley2, Mary Robinson1, Stefan Tiefenbacher1. 1Esoterix Inc. /Colorado Coagulation / A LabCorp Company (Laboratory Corporation of America Holdings), Englewood, CO, USA. 2Diagnostica Stago, Inc, Parsippany, NJ, USA


150

PULMONARY HEMORRHAGE AS A COMPLICATION OF TRANSPLANTATION-ASSOCIATED THROMBOTIC MICROANGIOPATHY: AN INSTITUTIONAL EXPERIENCE
Sarah Sartain 1, Stacey Shubert2, Caridad Martinez2. 1Department of Pediatrics, Section of Hematology-Oncology, Texas Children, Houston, TX, USA. 2Department of Pediatrics, Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children, Houston, TX, USA


151

EFFICACY AND SAFETY OF FIBRINOGEN CONCENTRATE FOR ON-DEMAND TREATMENT OF ACUTE BLEEDING AND SURGICAL PROPHYLAXIS IN PEDIATRIC PATIENTS WITH CONGENITAL FIBRINOGEN DEFICIENCY
Bruce. A Schwartz1, Flora Peyvandi2, Sunil. D Lohade3, Fulton D'Souza4, G. S Latha5, Claudia Khayat6, Omid Zekavat7, Irina Kruzkhova8, Cristina Solomon8, Sigurd Knaub8. 1Clinical Research a Development, Octapharma, Hoboken, NJ, USA. 2Fondazione IRCCS CaGrandaOspedaleMaggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy. 3Sahyadri Specialty Hospital, Pune, India. 4St. John, Bangalore, India. 5S. S Institute of Medical Science and Research Center, Davangere, India. 6Hotel De Dieu de France, Beirut, Lebanon. 7Nemazee Hospital Shiraz University of Medical Sciences, Shiraz, Iran. 8Research a Development Department, Octapharma, Lachen, Switzerland


152

SINGLE-DOSE PHARMACOKINETICS OF FIBRINOGEN CONCENTRATE FOR ON-DEMAND TREATMENT OF ACUTE BLEEDING AND SURGICAL PROPHYLAXIS IN PEDIATRIC PATIENTS WITH CONGENITAL FIBRINOGEN DEFICIENCY
Bruce. A Schwartz1, Flora Peyvandi2, S. D Lohade3, Fulton D'Souza4, G. S Latha5, Claudia Khayat6, Omid Zekavat7, Irina Kruzhkova8, Cristina Solomon8, Sigurd Knaub8. 1Clinical Research a Development, Octapharma, Hoboken, NJ, USA. 2Fondazione IRCCS CaGrandaOspedaleMaggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy. 3Sahyadri Specialty Hospital, Pune, India. 4St. John, Bangalore, India. 5S. S Institute of Medical Science and Research Center, Davangere, India. 6Hotel De Dieu de France, Beirut, Lebanon. 7Nemazee Hospital Shiraz University of Medical Sciences, Shiraz, Iran. 8Research a Development Department, Octapharma, Lachen, Switzerland


154

A NOVEL PATHOGENIC VARIANT WITHIN THE FACTOR XIII ACTIVE SITE PRESENTING AS SEVERE UMBILICAL HEMORRHAGE
Kaitlin L. Strumph, Jennifer G. Davila, William B. Mitchell. Division of Hematology/Oncology, The Children's Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, USA


155

EFFICACY AND SAFETY OF BAY 94-9027 PROPHYLAXIS IS SUSTAINED FOR UP TO >2 YEARS: OUTCOMES IN 23 PATIENTS AGED ≥12 YEARS IN THE PROTECT KIDS STUDY AND EXTENSION
Sanjay Ahuja1, Jonathan M. Ducore2, Olubunmi Afonja3, Maria Wang3, Bryce A. Kerlin4. 1Rainbow Babies a Children, Cleveland, OH, USA. 2University of California Davis Medical Center, Sacramento, CA, USA. 3Bayer, Whippany, NJ, USA. 4Nationwide Children's Hospital, Columbus, OH, USA


156

INDEPENDENT EVALUATION OF A NEW CHROMOGENIC FACTOR VIII ASSAY KIT
Julie I. Tange, Nahla Heikal, Dong Chen, Rajiv Pruthi. Comprehensive Hemophilia Center and Division of Hematopathology, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA


157

RAPID DIAGNOSIS OF THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) USING A NEW FULLY-AUTOMATED CHEMILUMINESCENT ASSAY FOR ADAMTS13 ACTIVITY.
Pierre A Toulon1, Ines Harzallah2. 1Pasteur University Hospital, Hematology, Nice, France. 2Regional Hospital, Hematology, Mulhouse, France


158

THE HEMOSTATIC AND FIBRINOLYTIC ABNORMALITIES IN TRAUMA-INDUCED COAGULOPATHY
Mark Walsh, MD1, Hau C. Kwaan, MD2, Jordan Hatch, BS3, Faran Bokhari, MD, FACS4, Scott Thomas, MD5. 1St. Joseph Regional Medical Center, Mishawaka, IN, USA. 2Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. 3Indiana University School of Medicine, South Bend, IN, USA. 4John H. Stroger, Jr. Hospital, Chicago, IL, USA. 5Beacon Health Systems, South Bend, IN, USA


159

PULMONARY VEIN THROMBOSIS ASSOCIATED WITH A LARGE HIATAL HERNIA
Yu Zhao, Reynold Andika, Richard Alweis. Rochester Regional Health/Unity Hospital, Rochester, NY, USA


A8. ANTITHROMBOTIC THERAPY


0

VENOUS THROMBOEMBOLISM INCIDENCE AMONG PATIENTS RECOMMENDED FOR PHARMACOLOGIC THROMBOEMBOLISM PROPHYLAXIS AFTER CESAREAN DELIVERY IN SELECTED GUIDELINES
Jerome J Federspiel1, 2, Lauren E Wein1, Kateena L Addae-Konadu1, Kristin C Darwin2, Laura E Talamo3, Evan R Myers4, 5, Andra H James1. 1Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Duke University School of Medicine, Durham, NC, USA. 2Department of Gynecology and Obstetrics, The Johns Hopkins School of Medicine, Baltimore, MD, USA. 3Division of Hematology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA. 4Division of Reproductive Sciences, Department of Obstetrics and Gynecology, Duke University School of Medicine, Durham, NC, USA. 5Duke Clinical Research Institute, Durham, NC, USA


A9. INFORMATIONAL ABSTRACT (POSTER ONLY)


160

TWELVE-MONTH INTERIM ANALYSIS OF EFFICACY AND SAFETY OF GIVOSIRAN, AN RNAI THERAPEUTIC FOR AHP, IN THE ENVISION OPEN LABEL EXTENSION
John P. Smith. University of Utah, Salt Lake City, UT, USA


161

PROGNOSTIC CATEGORISATION OF AML PATIENTS BASED ON CD7 AND CD56 EXPRESSION-A TERTIARY CARE CENTER STUDY IN NORTHERN INDIA
Sandeep Rai1, Prof Ritu Gupta2, Saroj Singh3. 1Lab Oncology, AIIMS, New Delhi, India. 2Lab Oncology, AIIMS, New Delhi, India. 3Lab Oncology, AIIMS, New Delhi, India

7:00 - 8:00 PM
SHORT TALKS
THROMBOSIS: CLINICAL


DEVELOPMENT OF A BRIEF SCREENING TOOL FOR EMOTIONAL HARM ASSOCIATED WITH VENOUS THROMBOEMBOLISM
Keith S. Keddington1, Aubrey E. Jones1, Michael Feehan2, Daniel M. Witt1. 1University of Utah College of Pharmacy, Department of Pharmacotherapy, Salt Lake City, UT, USA. 2Kantar LLC, Boston, MA, USA


VENOUS THROMBOEMBOLISM IN PATIENTS WITH UTERINE FIBROIDS
Hira Latif1, Valentina Baez Sosa1, Stephen J. Fernandez2, Nicholas D. Hazen1, James K. Robinson1, Vadim Morozov1, Kelly W. Fitzpatrick1. 1MedStar Washington Hospital Center, Washington, DC, USA. 2MedStar Health Research Institute, Washington, DC, USA


RACIAL DISPARITIES ACROSS AGE GROUPS IN ILLINOIS HOSPITAL ADMISSIONS FOR PULMONARY EMBOLISM
Karlyn Martin1, Megan McCabe2, Joseph Feinglass3, Sadiya Khan2. 1Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 2Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 3Division of General Internal Medicine and Geriatrics, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA


CHOICE OF ANTICOAGULATION THERAPY AND PERSISTENCE AMONG PATIENTS WITH ATRIAL FIBRILLATION FOLLOWING A SHARED DECISION-MAKING ENCOUNTER
Jeff Nagge1, Sherilyn Houle1, Eunice Chan1, Kristen Stypa1, Ai-Leng Foong1, Ryan McKee2. 1University of Waterloo, Kitchener, ON, Canada. 2Centre for Family Medicine, Kitchener, ON, Canada